INDEPENDENT RESEARCH MONITOR
About & methodology
How MyelinWatch selects, classifies and explains research without overstating the evidence.
About & methodology
How MyelinWatch selects, classifies and explains research without overstating the evidence.
What MyelinWatch tracks
MyelinWatch systematically monitors MS-relevant research on remyelination, myelin repair and closely related neurorepair. It follows clinical registries, peer-reviewed research and carefully selected translational programmes. Positive, negative, null, paused and stopped programmes remain part of the record.
How evidence is classified
Human efficacy data are kept distinct from safety or pharmacokinetic studies, registered or planned trials, animal studies and cell-only work. Changes in VEP, magnetization transfer ratio, myelin water fraction, PET or other biomarkers are not presented as proven clinical benefit.
What counts as an update
The monitor prioritises trial registration, first dosing, recruitment or protocol changes, pauses, terminations, safety signals, regulatory action, results, peer-reviewed publication and major translational milestones. Repeated publicity without a substantive change is not promoted as a major update.
A deliberately broad search
The project looks beyond the word remyelination. Monitoring includes myelin repair and regeneration, promyelination, oligodendrocyte differentiation and maturation, OPC biology, neurorepair, glial or neural progenitors and remyelination-linked neuroprotection.
Editorial boundary
Automated monitoring creates a review queue; it does not publish medical conclusions. Public records are added only after source review and conservative clinical interpretation. MyelinWatch is informational and is not medical advice.